Ftse Mib
36.267,63
1,25%
DAX
20.903,39
1,31%
S&P 500
5.996,66
1,00%
NASDAQ
19.630,20
1,51%
Bitcoin
100.183,46
-0,82%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ BioXcel Therapeutics Inc (BTAI) BioXcel Therapeutics Inc (BTAI) Notizie

BTAI

BioXcel Therapeutics (BTAI)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:BTAI
DataOraFonteTitoloSimboloCompagnia
16/01/202514:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BTAIBioXcel Therapeutics Inc
11/01/202502:03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BTAIBioXcel Therapeutics Inc
10/01/202522:45Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:BTAIBioXcel Therapeutics Inc
30/12/202422:15Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:BTAIBioXcel Therapeutics Inc
18/12/202423:16Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:BTAIBioXcel Therapeutics Inc
16/12/202421:59Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BTAIBioXcel Therapeutics Inc
25/11/202412:00Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:BTAIBioXcel Therapeutics Inc
22/11/202414:16GlobeNewswire Inc.BioXcel Therapeutics Announces Pricing of $7.0 Million Public OfferingNASDAQ:BTAIBioXcel Therapeutics Inc
21/11/202422:47GlobeNewswire Inc.BioXcel Therapeutics Announces Proposed Public OfferingNASDAQ:BTAIBioXcel Therapeutics Inc
14/11/202415:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BTAIBioXcel Therapeutics Inc
14/11/202413:00GlobeNewswire Inc.BioXcel Therapeutics Reports Third Quarter 2024 Financial ResultsNASDAQ:BTAIBioXcel Therapeutics Inc
12/11/202413:00GlobeNewswire Inc.BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer’s DementiaNASDAQ:BTAIBioXcel Therapeutics Inc
08/11/202413:00GlobeNewswire Inc.BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024NASDAQ:BTAIBioXcel Therapeutics Inc
29/10/202412:00GlobeNewswire Inc.BioXcel Therapeutics to Present at ThinkEquity ConferenceNASDAQ:BTAIBioXcel Therapeutics Inc
15/10/202413:00GlobeNewswire Inc.BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress DisorderNASDAQ:BTAIBioXcel Therapeutics Inc
19/09/202413:00GlobeNewswire Inc.BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for AgitationNASDAQ:BTAIBioXcel Therapeutics Inc
18/09/202401:17Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:BTAIBioXcel Therapeutics Inc
05/09/202413:00GlobeNewswire Inc.BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or SchizophreniaNASDAQ:BTAIBioXcel Therapeutics Inc
07/08/202413:00GlobeNewswire Inc.BioXcel Therapeutics to Participate in Canaccord Genuity 44th Annual Growth ConferenceNASDAQ:BTAIBioXcel Therapeutics Inc
06/08/202413:00GlobeNewswire Inc.BioXcel Therapeutics Reports Second Quarter 2024 Financial ResultsNASDAQ:BTAIBioXcel Therapeutics Inc
30/07/202413:00GlobeNewswire Inc.BioXcel Therapeutics to Report Second Quarter 2024 Financial Results on August 6, 2024NASDAQ:BTAIBioXcel Therapeutics Inc
16/07/202413:00GlobeNewswire Inc.BioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales of IGALMI™ (dexmedetomidine) Sublingual FilmNASDAQ:BTAIBioXcel Therapeutics Inc
25/06/202413:00GlobeNewswire Inc.BioXcel Therapeutics Announces Positive Topline Results from Post-Marketing Requirement Study Evaluating PRN Treatment of IGALMI™ (dexmedetomidine) Sublingual Film for Agitation Associated with Bipolar Disorders or SchizophreniaNASDAQ:BTAIBioXcel Therapeutics Inc
04/06/202413:30Edgar (US Regulatory)Form 424B7 - Prospectus [Rule 424(b)(7)]NASDAQ:BTAIBioXcel Therapeutics Inc
28/05/202413:00GlobeNewswire Inc.BioXcel Therapeutics to Present at Jefferies Global Healthcare ConferenceNASDAQ:BTAIBioXcel Therapeutics Inc
21/05/202413:00GlobeNewswire Inc.BioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual MeetingNASDAQ:BTAIBioXcel Therapeutics Inc
09/05/202413:00GlobeNewswire Inc.BioXcel Therapeutics Reports First Quarter 2024 Financial ResultsNASDAQ:BTAIBioXcel Therapeutics Inc
25/04/202413:00GlobeNewswire Inc.BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024NASDAQ:BTAIBioXcel Therapeutics Inc
24/04/202416:30GlobeNewswire Inc.BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual MeetingNASDAQ:BTAIBioXcel Therapeutics Inc
22/04/202413:00GlobeNewswire Inc.BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market PotentialNASDAQ:BTAIBioXcel Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:BTAI

La tua Cronologia

BIT
STLAM
Stellantis NV
BIT
ENEL
Enel
BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
ENI
Eni
BIT
LDO
Leonardo
BIT
SRG
Snam
BIT
STMMI
ST Microelectronics
BIT
CPR
Davide Campari
BIT
RACE
Ferrari NV
BIT
BPE
Bper Banca
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
SPM
Saipem
BIT
IVG
Iveco Group NV
BIT
MONC
Moncler
BIT
NEXI
Nexi S.p.A
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network